GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » EV-to-FCF
中文

IRIDEX (IRIDEX) EV-to-FCF : -6.35 (As of Apr. 25, 2024)


View and export this data going back to 1996. Start your Free Trial

What is IRIDEX EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, IRIDEX's Enterprise Value is $43.50 Mil. IRIDEX's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.85 Mil. Therefore, IRIDEX's EV-to-FCF for today is -6.35.

The historical rank and industry rank for IRIDEX's EV-to-FCF or its related term are showing as below:

IRIX' s EV-to-FCF Range Over the Past 10 Years
Min: -157.46   Med: -2.91   Max: 775.29
Current: -6.35

During the past 13 years, the highest EV-to-FCF of IRIDEX was 775.29. The lowest was -157.46. And the median was -2.91.

IRIX's EV-to-FCF is ranked worse than
100% of 372 companies
in the Medical Devices & Instruments industry
Industry Median: 25.71 vs IRIX: -6.35

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), IRIDEX's stock price is $2.94. IRIDEX's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.590. Therefore, IRIDEX's PE Ratio for today is At Loss.


IRIDEX EV-to-FCF Historical Data

The historical data trend for IRIDEX's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX EV-to-FCF Chart

IRIDEX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.65 -8.23 9.47 -2.04 -6.04

IRIDEX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.04 -2.44 -3.38 -4.77 -6.04

Competitive Comparison of IRIDEX's EV-to-FCF

For the Medical Devices subindustry, IRIDEX's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRIDEX's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where IRIDEX's EV-to-FCF falls into.



IRIDEX EV-to-FCF Calculation

IRIDEX's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=43.495/-6.854
=-6.35

IRIDEX's current Enterprise Value is $43.50 Mil.
IRIDEX's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRIDEX  (NAS:IRIX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

IRIDEX's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.94/-0.590
=At Loss

IRIDEX's share price for today is $2.94.
IRIDEX's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.590.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


IRIDEX EV-to-FCF Related Terms

Thank you for viewing the detailed overview of IRIDEX's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


IRIDEX (IRIDEX) Business Description

Traded in Other Exchanges
N/A
Address
1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Executives
Nandini Devi director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp 10 percent owner 75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp 10 percent owner 111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous director C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda director 402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer officer: COO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne director
Robert A Gunst director
David Bruce director, officer: President and CEO 1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum director
Romeo R Dizon other: Vice President and Controller 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043

IRIDEX (IRIDEX) Headlines

From GuruFocus

Iridex to Participate in Fireside Chat with Stifel Equity Research

By Value_Insider Value_Insider 12-06-2022

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-01-2022

Iridex Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023

Iridex Announces First Quarter 2022 Financial Results

By PurpleRose PurpleRose 07-11-2022

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-12-2022